Global study digs into Real-World prostate cancer care
NCT ID NCT06200558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers information from medical records of 534 people with metastatic prostate cancer worldwide. It looks at how well different treatments work in everyday practice, including hormone therapy, a radioactive drug called Lutetium-177, and PARP inhibitors. The goal is to learn from real experiences to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale di Macerata
RECRUITINGProvince of Macerata, Macerata, 62100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?